European Regulators’ Decision Boosts HTG Molecular Diagnostics (HTGM); bebe stores (BEBE) Evaluating Strategic Options


HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM) shares soared over 50% in the extended session Wednesday after the company said that health regulators in the European Union gave CE mark to its genetic lung-cancer diagnostic test HTG EdgeSeq ALKPlus Assay EU, allowing its commercial sale in Europe.

HTGM stock closed at $2.14, up $0.17 (or +8.63%) and 467,675 of its shares changed hands during the day.

HTG Molecular Diagnostics, which develops and markets technology platforms that facilitate the routine use of complex molecular profiling, has 7.07M shares outstanding and HTGM stock 52-week range is from $1.20 to $4.45 per share. At close on Wednesday, the company had a market capitalization of $15.12M



Shares of bebe stores, inc. (Nasdaq:BEBE) surged more than 6% in after-hours trading Wednesday as the global specialty retailer said that it is evaluating its strategic options with B. Riley & Co. as financial advisor, adding that there is no certainty that any specific transaction will be reached.

Last month, bebe stores reported a net loss of $5.2 million or $0.65 per share for its second quarter fiscal 2017.

BEBE stock finished the regular session in positive territory by 8.12% (or +$0.29) at $3.86 with a total volume of 547,620 shares traded, representing a large increase in activity versus its average volume (3m) of 60,605 shares.

bebe stores, which designs, develops, and produces women’s apparel and accessories, has 8.07M shares outstanding, market capitalization (intraday) of $28.80M and BEBE stock one-year range is between $3.13 and $9.10 per share


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at